Association between cytochrome P450 2D6 genotype and harm avoidance

被引:40
|
作者
Roberts, RL
Luty, SE
Mulder, RT
Joyce, PR
Kennedy, MA
机构
[1] Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand
[2] Christchurch Sch Med & Hlth Sci, Dept Psychol Med, Christchurch, New Zealand
关键词
CYP2D6; genotype; personality; brain; harm avoidance; novelty seeking;
D O I
10.1002/ajmg.b.20163
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Genetic polymorphisms within the serotonergic and dopaminergic neurotransmitter systems may be associated with heightened harm avoidance and novelty seeking. It is also conceivable that polymorphisms in enzymes that mediate the metabolism of endogenous amines within the brain may influence these components of temperament. The CYP2D6 enzyme is expressed at low levels in the brain, and has been shown to mediate the formation of the neurotransmitters serotonin and dopamine from trace amines. Some 5-10% of Caucasians are CYP2D6 deficient due to inactivating mutations in the CYP2D6 gene, and are termed poor metabolizers (PMs). In this study, we investigated whether temperament varied significantly between PMs and CYP2D6 extensive metabolizers (EMs) using the Temperament and Character Inventory (TCI). CYP2D6 genotypes were determined for 121 depressed patients. Of these patients, 113 were inferred from genotype as being EMs and eight as PMs. A significant difference in temperament was observed between inferred CYP2D6 EM and PM individuals. CYP2D6 PMs had significantly lower harm avoidance scores (P = 0.003) than EMs. Furthermore, analysis of the harm avoidance sub-scales revealed that the CYP2D6 PMs scored significantly lower on "fear of uncertainty" (P < 0.001), fatigability (P = 0.009), and shyness (P = 0.038) than EMs, but did not differ significantly from EMs on the worry/pessimism sub-scale. No significant difference in character scores was detected between inferred CYP2D6 EMs and PMs. Our findings suggest that the CYP2D6 polymorphism may impact on personality, and one potential mechanism for this would be by influencing the generation of endogenous neurotransmitters in the brain. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:90 / 93
页数:4
相关论文
共 50 条
  • [31] Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy
    Ververs, F. F. Tessa
    Voorbij, Heronimus A. M.
    Zwarts, Petra
    Belitser, Svetlana V.
    Egberts, Toine C. G.
    Visser, Gerard H. A.
    Schobben, Alfred F. A. M.
    CLINICAL PHARMACOKINETICS, 2009, 48 (10) : 677 - 683
  • [32] Cytochrome P450 2D6 genotype partially explains interindividual pharmacokinetic variability of perazine and desmethylperazine
    Brockmöller, J
    Schmider, J
    Sachse, C
    Schley, J
    Müller-Oerlinghausen, B
    Roots, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R163 - R163
  • [33] Metabolic Activation of Atomoxetine Mediated by Cytochrome P450 2D6
    You, Yutong
    Wang, Xu
    Ma, Kaiqi
    Li, Jiaru
    Peng, Ying
    Zheng, Jiang
    CHEMICAL RESEARCH IN TOXICOLOGY, 2021, 34 (09) : 2135 - 2144
  • [34] Rapid and reliable method for cytochrome P450 2D6 genotyping
    Stamer, UM
    Bayerer, B
    Wolf, S
    Hoeft, A
    Stüber, F
    CLINICAL CHEMISTRY, 2002, 48 (09) : 1412 - 1417
  • [35] SUBSTRATE SPECIFICITY OF CYTOCHROME P450 2D6 GENETIC VARIANTS
    van der Lee, M.
    Guchelaar, H.
    Swen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S9 - S9
  • [36] Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen
    Dong, HJ
    Haining, RL
    Thummel, KE
    Rettie, AE
    Nelson, SD
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (12) : 1397 - 1400
  • [37] Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects
    Pei, Qi
    Peng, Jinfu
    Tan, Hongyi
    Yang, Liu
    Yang, Xiding
    Liu, Li
    Liu, Shikun
    Yuan, Hong
    Yang, Guoping
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (04) : 427 - 433
  • [38] Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects
    Qi Pei
    Jinfu Peng
    Hongyi Tan
    Liu Yang
    Xiding Yang
    Li Liu
    Shikun Liu
    Hong Yuan
    Guoping Yang
    European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40 : 427 - 433
  • [39] Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia
    Stedman, CAM
    Begg, EJ
    Kennedy, MA
    Roberts, R
    Wilkinson, TJ
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (04) : 187 - 190
  • [40] Treatment of codeine dependence with inhibitors of cytochrome P450 2D6
    Fernandes, LC
    Kilicarslan, T
    Kaplan, HL
    Tyndale, RF
    Sellers, EM
    Romach, MK
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (03) : 326 - 329